AUPH

Aurinia Pharmaceuticals Inc.

A biopharmaceutical company in Victoria, British Columbia, that develops and sells treatments for autoimmune diseases. Its signature drug, LUPKYNIS (voclosporin), is an oral medicine for adults with lupus nephritis, a kidney inflammation caused by lupus. The company began in 1993 in Edmonton as Isotechnika Pharma, then took the Aurinia name in 2013 when it acquired Aurinia Pharma Corp. and refocused on voclosporin; the drug won US approval in 2021. The brand name Lupkynis blends "lupus" with a distinctive suffix, and "Aurinia" also names a golden-flowered garden plant called basket of gold.